AGEN Agenus Inc

$AGEN specialist bio funds have taken very large positions (up to just short of 10% where reporting is required) so id expect much more price support than what we’ve seen in the past. Agenus is no longer a good short in my opinion.

$AGEN been here for years. Almost $10 now per share. Another $10 for me to break even. And then hopefully finally going green!

$AGEN just look at the $KOD chart… proof that heavily diluted biotech stocks can fully reverse as long as the team executes and the drug brings positive results. We will see this above $100 by the end of next year. Congrats to the bulls. Congrats to I hope you all believers can retire soon off of this!

$AGEN basically Dr. Kasi has proven to me that bot bal works. That’s why I own my shares.

$AGEN Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19

$AGEN I am not surprised that AGEN share price is going higher. I am also not surprised that Biotechguy21 doesn't post 23x per day.

$AGEN We are really close to a breakout to $12. AI says "Once it manages a clean breakout above the $8.76 – $8.85 window, technical indicators show a lack of immediate structural resistance directly above, creating a psychological runway toward double digits."

$AGEN Very powerful close. Agenus turns cold tumors Hot melting them away. Best in Class! Bot Bal amazing.

$AGEN Today was enjoyable, but don't be dismayed if this gives some of the gain back at some point. There is a long road ahead. Being patient is difficult but necessary if one is to give oneself an opportunity to succeed. Over the years I have come to more readily accept the timelines involved. The financial issues here are well understood, but I still believe there is a fundamental misunderstand of the onerous timelines in bringing drugs to market. Even the most successful drugs. For instance, Keytruda, a massive success by any measure. It was originally conceived way back in 2003 by a company called Organon. I do not know all of the mechanics which brought it to Merck, but I assume it was through a buyout of some sort. Merck eventually moved it into advanced development in 2009, and it was finally approved in 2016, a full 13 years from original concept! This takes a long time, even when being controlled by giants.

$AGEN ... Over 1200 ( and climbing) patients have been treated over the years with no deaths. With only common and treatable side effects... Everyone knows Neo-adjuvant SOC is in the dark ages for CRC....We ALSO know BAL/BOT works with outstanding results in the CRC neo-adjuvant setting ... IMHO ... Once we can get Phase 3 finally up and running... Will anyone of us be surprised with a AA in the second half of next year?... I for one would be surprised if we don't get AA.

$AGEN Rodman & Renshaw initiated coverage on Agenus Inc. (NASDAQ:AGEN) with a buy rating and a price target of $19.00.

$AGEN Intresting timing on this Catalyst , All top brass locked and loaded the new board member got his stock and options then the $40 buy gets put out right after he is set up. I think we will see a strong 3 year update on or about the 1st. Get ready imo LEXINGTON, Mass., September 10, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

$AGEN . Neoadjuvant BOT/BAL was safe and did not delay planned surgery in any patient. The major pathologic response rate was 41% (95% CI, 21%–64%) for pMMR, and 100% (95% CI, 40%–100%) for dMMR CRC

$AGEN This upward move is justified with just CRC data. IMO, A positive readout of data for ovarian cancer on October 3 would move AGEN stock into an extremely bullish mode. Im not even sure how to put a value on it if that's the case. There will be even more reason for FDA approval. fingers crossed.

$AGEN On the latest episode of #OncologyUnplugged 🔌, host Chandler Park, M.D., F.A.C.P., of Norton Cancer Insitute, sits down with Pashtoon Kasi, MD, MS, of City of Hope Orange County, to discuss what may be one of the most significant paradigm shifts in CRC management: moving immunotherapy up front. Their conversation covers: 🔬 Why the high neoantigen load of dMMR/MSI-H tumors makes them so sensitive to checkpoint blockade 📊 The path from the phase 3 ATOMIC trial to the NICHE series, where a brief course of neoadjuvant nivolumab plus a single dose of ipilimumab produced near-universal responses 🧪 Dr Kasi's NEST trials of botensilimab plus balstilimab, which extended activity into the larger MSS population 🧬 Mechanistic insights, including an "inside-out" response pattern, regulatory T-cell depletion, and why an intact tumor and lymph nodes may matter ctDNA as an emerging surrogate end point, the STELLAR-303 data in MSS diseaseliver metastases as an immunosuppressive niche

$AGEN the resident shorts on this board are conspicuously absent… miss you guys It won’t be the same discussion without your unyielding negativity.

$AGEN So it looks like BotBal is really the leading treatment for CRC and it's a not a close race. Neo adjuvant treatment results are fantastic. So many need this option and so I think the FDA will finally be pressured to move on approval. That's not optimum but it's the nature of Agenus to work this way. This may be by necessity due to BP politics. I think we see a much higher stock price coming our way in 2027. Now we need another front to attack . My vote is for pancreatic or melonoma!!. Come on Dr Chand/ Dr O'Day , You can develop a modification to another treatment. A big break through would be so nice!!

$AGEN Dr. Kassi and City oh Hope are opening multiple sites nation wide for Nest 3. I think that this is an excellent news, and look forward to first data reports. This is nothing short of a miracle for Agenus, and every day it becomes more clear that I hope that Bot/Bali are likely to become a SOC in not so distant future. Best of all, Agenus only provides Bot/Bali and no additional cost to them

$AGEN This is going to get absolutely pummelled tomorrow morning, kiss goodbye to the $6’s and welcome to the $5’s Thanks to our ”Great Leader” and the Zionist scum who control him and all of our politicians the entire global financial system is on the edge of collapse and inflation will be going through the roof! when are people going to wake up?

$AGEN Angelo de Claro has been named director of the FDA Oncology Center of Excellence. Project Front Runner : initiative toward having discussions with sponsors about moving clinical trials into the frontline or earlier disease settings. Agenus recently scrapped it’s late stage CRC phase 3 for a phase 3 frontline/adjuvant setting. Interesting….